Opus Capital Group’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $320K | Hold |
34,700
| – | – | 0.04% | 92 |
|
|
2025
Q1 | $298K | Hold |
34,700
| – | – | 0.04% | 95 |
|
|
2024
Q4 | $373K | Buy |
34,700
+2,000
| +6% | +$21.5K | 0.05% | 84 |
|
|
2024
Q3 | $186K | Hold |
32,700
| – | – | 0.02% | 116 |
|
|
2024
Q2 | $138K | Buy |
32,700
+2,200
| +7% | +$9.28K | 0.02% | 115 |
|
|
2024
Q1 | $155K | Hold |
30,500
| – | – | 0.02% | 119 |
|
|
2023
Q4 | $284K | Hold |
30,500
| – | – | 0.05% | 100 |
|
|
2023
Q3 | $200K | Buy |
30,500
+4,000
| +15% | +$26.2K | 0.04% | 110 |
|
|
2023
Q2 | $215K | Hold |
26,500
| – | – | 0.04% | 115 |
|
|
2023
Q1 | $227K | Hold |
26,500
| – | – | 0.04% | 110 |
|
|
2022
Q4 | $245K | Buy |
26,500
+10,000
| +61% | +$92.5K | 0.05% | 103 |
|
|
2022
Q3 | $170K | Hold |
16,500
| – | – | 0.04% | 105 |
|
|
2022
Q2 | $165K | Hold |
16,500
| – | – | 0.03% | 109 |
|
|
2022
Q1 | $203K | Hold |
16,500
| – | – | 0.04% | 106 |
|
|
2021
Q4 | $286K | Hold |
16,500
| – | – | 0.06% | 88 |
|
|
2021
Q3 | $296K | Buy |
16,500
+6,000
| +57% | +$108K | 0.07% | 83 |
|
|
2021
Q2 | $240K | Buy |
10,500
+500
| +5% | +$11.4K | 0.05% | 102 |
|
|
2021
Q1 | $150K | Hold |
10,000
| – | – | 0.04% | 124 |
|
|
2020
Q4 | $54K | Hold |
10,000
| – | – | 0.01% | 127 |
|
|
2020
Q3 | $46K | Buy |
+10,000
| New | +$46K | 0.01% | 116 |
|